- Home
- FMY vs MCRB Comparison
FMY vs MCRB Comparison
Compare FMY & MCRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FMY | MCRB |
|---|---|---|
| Founded | 2005 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.0M | 47.4M |
| IPO Year | 2005 | 2015 |
Fundamental Metrics
Financial Performance| Metric | FMY | MCRB |
|---|---|---|
| Price | $11.43 | $5.00 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $14.00 |
| AVG Volume (30 Days) | 2.6K | ★ 58.5K |
| Earning Date | 01-01-0001 | 05-11-2026 |
| Dividend Yield | ★ 6.98% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $789,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.40 | $4.32 |
| 52 Week High | $12.38 | $29.98 |
Technical Indicators
Market Signals| Indicator | FMY | MCRB |
|---|---|---|
| Relative Strength Index (RSI) | 39.70 | 48.84 |
| Support Level | N/A | $4.59 |
| Resistance Level | $11.80 | $5.65 |
| Average True Range (ATR) | 0.12 | 0.26 |
| MACD | -0.01 | 0.10 |
| Stochastic Oscillator | 1.91 | 72.46 |
Price Performance
Historical ComparisonAbout FMY First Trust Motgage Income Fund of Beneficial Interest
First Trust Mortgage Income Fund is a United States-based diversified, closed-end management investment company. The fund's primary investment objective is to seek a high level of current income. Its secondary investment objective is to preserve capital. The fund pursues its objectives by investing predominantly in mortgage-backed securities representing part ownership in a pool of either residential or commercial mortgage loans that, in the opinion of the Fund's investment advisor, offer an attractive combination of credit quality, yield, and maturity.
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a clinical-stage biotechnology company focused on the development of live biotherapeutic candidates. Its pipeline includes candidates such as SER-155 and SER-603, aimed at preventing and treating bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases. The company operates as a single reportable segment, mainly developing microbiome-based therapies targeting bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases.